| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 90 | 2015 | 5061 | 4.740 |
Why?
|
| Carcinoma, Pancreatic Ductal | 40 | 2015 | 1724 | 3.920 |
Why?
|
| Common Bile Duct Neoplasms | 9 | 2015 | 145 | 2.170 |
Why?
|
| Adenocarcinoma | 45 | 2015 | 7789 | 2.150 |
Why?
|
| Ampulla of Vater | 7 | 2015 | 155 | 2.030 |
Why?
|
| Pancreaticoduodenectomy | 24 | 2015 | 690 | 1.560 |
Why?
|
| Neoadjuvant Therapy | 24 | 2015 | 4975 | 1.180 |
Why?
|
| Duodenal Neoplasms | 7 | 2013 | 138 | 1.080 |
Why?
|
| Pancreas | 9 | 2015 | 718 | 1.060 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 6 | 2009 | 89 | 1.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 5 | 2008 | 27 | 0.990 |
Why?
|
| Biomarkers, Tumor | 23 | 2015 | 10331 | 0.900 |
Why?
|
| PTEN Phosphohydrolase | 7 | 2014 | 986 | 0.870 |
Why?
|
| Neoplasm Invasiveness | 19 | 2014 | 3981 | 0.830 |
Why?
|
| Immunohistochemistry | 33 | 2015 | 7548 | 0.820 |
Why?
|
| Pancreatic Ducts | 4 | 2014 | 122 | 0.740 |
Why?
|
| Tissue Array Analysis | 11 | 2015 | 760 | 0.680 |
Why?
|
| Mesenteric Artery, Superior | 3 | 2015 | 71 | 0.630 |
Why?
|
| Prognosis | 34 | 2015 | 21713 | 0.620 |
Why?
|
| ErbB Receptors | 7 | 2015 | 2295 | 0.620 |
Why?
|
| Aged, 80 and over | 45 | 2015 | 29902 | 0.590 |
Why?
|
| Middle Aged | 74 | 2015 | 86204 | 0.590 |
Why?
|
| Cytochrome P-450 Enzyme System | 6 | 2000 | 200 | 0.550 |
Why?
|
| Aged | 61 | 2015 | 70117 | 0.540 |
Why?
|
| Oxidoreductases, N-Demethylating | 4 | 2000 | 41 | 0.530 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 4 | 2000 | 78 | 0.520 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2015 | 44 | 0.520 |
Why?
|
| NF-kappa B | 7 | 2014 | 1549 | 0.520 |
Why?
|
| Receptors, Somatomedin | 1 | 2015 | 70 | 0.510 |
Why?
|
| Female | 87 | 2015 | 141928 | 0.510 |
Why?
|
| Humans | 142 | 2015 | 261506 | 0.490 |
Why?
|
| Phosphoprotein Phosphatases | 2 | 2013 | 214 | 0.490 |
Why?
|
| Adult | 60 | 2015 | 77950 | 0.490 |
Why?
|
| Male | 79 | 2015 | 123000 | 0.480 |
Why?
|
| Cullin Proteins | 1 | 2013 | 41 | 0.480 |
Why?
|
| Kaplan-Meier Estimate | 17 | 2015 | 6207 | 0.470 |
Why?
|
| Pancreatectomy | 10 | 2014 | 652 | 0.460 |
Why?
|
| F-Box Proteins | 1 | 2013 | 96 | 0.450 |
Why?
|
| Glioma | 6 | 2009 | 1963 | 0.450 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2014 | 2488 | 0.440 |
Why?
|
| Carcinoma in Situ | 2 | 2013 | 487 | 0.440 |
Why?
|
| Neoplasm Proteins | 5 | 2014 | 3230 | 0.430 |
Why?
|
| Giant Cells | 1 | 2012 | 69 | 0.430 |
Why?
|
| SOX9 Transcription Factor | 1 | 2013 | 170 | 0.430 |
Why?
|
| Organoplatinum Compounds | 9 | 2015 | 702 | 0.420 |
Why?
|
| Precancerous Conditions | 4 | 2015 | 1058 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 25 | 2014 | 8873 | 0.410 |
Why?
|
| Pancreatic Cyst | 2 | 2010 | 107 | 0.410 |
Why?
|
| Biliary Tract | 1 | 2011 | 37 | 0.410 |
Why?
|
| Proteolysis | 1 | 2013 | 370 | 0.410 |
Why?
|
| Cyclin D1 | 1 | 2014 | 576 | 0.400 |
Why?
|
| Gene Expression Profiling | 9 | 2013 | 5159 | 0.390 |
Why?
|
| Cell Lineage | 1 | 2013 | 668 | 0.380 |
Why?
|
| Lymphatic Metastasis | 13 | 2015 | 4844 | 0.380 |
Why?
|
| Gallbladder Diseases | 1 | 2010 | 43 | 0.370 |
Why?
|
| Cell Nucleolus | 1 | 2010 | 89 | 0.370 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2011 | 170 | 0.370 |
Why?
|
| Deoxycytidine | 12 | 2014 | 1353 | 0.370 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2012 | 330 | 0.370 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2010 | 35 | 0.360 |
Why?
|
| Chemokine CXCL12 | 1 | 2010 | 132 | 0.360 |
Why?
|
| Cell Line, Tumor | 36 | 2015 | 14551 | 0.360 |
Why?
|
| Immunophenotyping | 3 | 2009 | 1681 | 0.360 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2011 | 167 | 0.360 |
Why?
|
| Basigin | 1 | 2009 | 20 | 0.350 |
Why?
|
| Polyps | 1 | 2010 | 74 | 0.350 |
Why?
|
| Disease-Free Survival | 14 | 2015 | 10001 | 0.350 |
Why?
|
| MAP Kinase Signaling System | 1 | 2013 | 848 | 0.350 |
Why?
|
| Neoplasm Staging | 19 | 2015 | 13658 | 0.340 |
Why?
|
| Chemotherapy, Adjuvant | 11 | 2015 | 3890 | 0.340 |
Why?
|
| Cell Proliferation | 20 | 2015 | 7226 | 0.330 |
Why?
|
| Phosphoproteins | 2 | 2014 | 1152 | 0.330 |
Why?
|
| Gastrointestinal Tract | 1 | 2011 | 324 | 0.330 |
Why?
|
| Gallbladder Neoplasms | 1 | 2010 | 245 | 0.310 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2010 | 650 | 0.310 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2009 | 360 | 0.310 |
Why?
|
| Adaptor Proteins, Signal Transducing | 5 | 2014 | 1439 | 0.310 |
Why?
|
| Neoplasm, Residual | 3 | 2015 | 1656 | 0.300 |
Why?
|
| Genes, ras | 5 | 2014 | 667 | 0.290 |
Why?
|
| Ovarian Neoplasms | 5 | 2010 | 4638 | 0.290 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 301 | 0.290 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2011 | 600 | 0.280 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2010 | 661 | 0.280 |
Why?
|
| Oncogenes | 1 | 2009 | 673 | 0.280 |
Why?
|
| Esophageal Neoplasms | 6 | 2012 | 3168 | 0.280 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2009 | 589 | 0.270 |
Why?
|
| RNA, Messenger | 9 | 2015 | 6150 | 0.270 |
Why?
|
| Brain Neoplasms | 6 | 2009 | 4849 | 0.260 |
Why?
|
| Diagnosis, Differential | 6 | 2013 | 4744 | 0.260 |
Why?
|
| Uterine Neoplasms | 1 | 2009 | 545 | 0.250 |
Why?
|
| Cell Differentiation | 2 | 2013 | 4078 | 0.250 |
Why?
|
| Cell Cycle Proteins | 3 | 2014 | 2045 | 0.250 |
Why?
|
| Up-Regulation | 7 | 2012 | 2450 | 0.250 |
Why?
|
| Treatment Outcome | 24 | 2015 | 32848 | 0.250 |
Why?
|
| RNA-Binding Proteins | 1 | 2010 | 984 | 0.250 |
Why?
|
| Down-Regulation | 4 | 2014 | 2074 | 0.240 |
Why?
|
| Chemoradiotherapy, Adjuvant | 5 | 2013 | 565 | 0.240 |
Why?
|
| Staining and Labeling | 2 | 2003 | 429 | 0.240 |
Why?
|
| Time Factors | 13 | 2015 | 12926 | 0.240 |
Why?
|
| Dysplastic Nevus Syndrome | 1 | 2003 | 50 | 0.230 |
Why?
|
| Multivariate Analysis | 6 | 2015 | 4298 | 0.230 |
Why?
|
| Animals | 46 | 2014 | 59536 | 0.230 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2014 | 1331 | 0.230 |
Why?
|
| Neurons | 2 | 2012 | 2287 | 0.230 |
Why?
|
| Panax | 1 | 2003 | 33 | 0.220 |
Why?
|
| Nevus, Pigmented | 1 | 2003 | 104 | 0.220 |
Why?
|
| Mice | 34 | 2014 | 34495 | 0.220 |
Why?
|
| Cyclooxygenase 2 | 3 | 2014 | 483 | 0.220 |
Why?
|
| Cathepsin E | 2 | 2013 | 6 | 0.220 |
Why?
|
| I-kappa B Kinase | 3 | 2012 | 250 | 0.220 |
Why?
|
| Transglutaminases | 3 | 2008 | 99 | 0.220 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 1265 | 0.220 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2013 | 703 | 0.220 |
Why?
|
| Gene Expression | 8 | 2014 | 3570 | 0.210 |
Why?
|
| Obesity | 1 | 2015 | 2884 | 0.210 |
Why?
|
| Panniculitis | 1 | 2002 | 58 | 0.210 |
Why?
|
| Microtomy | 1 | 2002 | 17 | 0.210 |
Why?
|
| Carcinoma | 3 | 2011 | 2578 | 0.210 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2015 | 347 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2015 | 15862 | 0.210 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2013 | 436 | 0.200 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2015 | 2231 | 0.200 |
Why?
|
| ras Proteins | 4 | 2014 | 770 | 0.200 |
Why?
|
| Proportional Hazards Models | 7 | 2015 | 4988 | 0.200 |
Why?
|
| CA-19-9 Antigen | 2 | 2013 | 144 | 0.200 |
Why?
|
| Paraffin Embedding | 1 | 2002 | 226 | 0.200 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2014 | 528 | 0.200 |
Why?
|
| Peptide Hydrolases | 2 | 2014 | 256 | 0.190 |
Why?
|
| Central Nervous System Diseases | 1 | 2002 | 129 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2014 | 2359 | 0.190 |
Why?
|
| Immunity, Cellular | 1 | 2003 | 419 | 0.190 |
Why?
|
| RNA, Small Interfering | 10 | 2013 | 2216 | 0.190 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2014 | 1299 | 0.190 |
Why?
|
| Blotting, Western | 7 | 2014 | 3536 | 0.190 |
Why?
|
| Portal Vein | 2 | 2013 | 355 | 0.180 |
Why?
|
| Transfection | 9 | 2014 | 2944 | 0.180 |
Why?
|
| Mixed Function Oxygenases | 2 | 1999 | 64 | 0.180 |
Why?
|
| DNA-Binding Proteins | 5 | 2014 | 4821 | 0.180 |
Why?
|
| Gene Knockdown Techniques | 5 | 2014 | 1077 | 0.180 |
Why?
|
| Survival Rate | 11 | 2014 | 12221 | 0.180 |
Why?
|
| Carcinogenesis | 3 | 2014 | 1026 | 0.180 |
Why?
|
| Preoperative Care | 5 | 2010 | 1529 | 0.180 |
Why?
|
| Transplantation, Heterologous | 6 | 2011 | 1082 | 0.180 |
Why?
|
| Colorectal Neoplasms | 6 | 2010 | 3578 | 0.180 |
Why?
|
| Lymphoma, T-Cell | 1 | 2002 | 361 | 0.170 |
Why?
|
| Pancreatic Stellate Cells | 3 | 2014 | 76 | 0.170 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 657 | 0.170 |
Why?
|
| Camptothecin | 4 | 2015 | 517 | 0.170 |
Why?
|
| Melanoma | 2 | 2008 | 5317 | 0.170 |
Why?
|
| Esophagogastric Junction | 3 | 2007 | 543 | 0.170 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2010 | 122 | 0.170 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2011 | 153 | 0.160 |
Why?
|
| Homeodomain Proteins | 3 | 2015 | 1143 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2015 | 3639 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2015 | 10035 | 0.160 |
Why?
|
| Disease Progression | 7 | 2014 | 6682 | 0.160 |
Why?
|
| Signal Transduction | 11 | 2014 | 11965 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2009 | 5437 | 0.160 |
Why?
|
| Brain | 5 | 2006 | 4113 | 0.160 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2012 | 1823 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 5 | 2012 | 4367 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2015 | 7551 | 0.160 |
Why?
|
| Enzyme Activation | 5 | 2012 | 1764 | 0.160 |
Why?
|
| Fibrosis | 4 | 2014 | 793 | 0.160 |
Why?
|
| Pancreatitis | 2 | 2012 | 267 | 0.160 |
Why?
|
| Progesterone | 1 | 2000 | 513 | 0.160 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2010 | 2326 | 0.160 |
Why?
|
| Imipramine | 1 | 1997 | 29 | 0.160 |
Why?
|
| Trans-Activators | 1 | 2004 | 1555 | 0.160 |
Why?
|
| Retrospective Studies | 20 | 2015 | 37905 | 0.150 |
Why?
|
| Neuroendocrine Tumors | 2 | 2014 | 634 | 0.150 |
Why?
|
| DNA Mismatch Repair | 2 | 2009 | 268 | 0.150 |
Why?
|
| Blood Loss, Surgical | 3 | 2011 | 309 | 0.150 |
Why?
|
| Genes, erbB-1 | 2 | 2009 | 101 | 0.150 |
Why?
|
| Lymph Nodes | 3 | 2014 | 2967 | 0.150 |
Why?
|
| Protein Array Analysis | 4 | 2014 | 501 | 0.150 |
Why?
|
| Case-Control Studies | 3 | 2013 | 6100 | 0.140 |
Why?
|
| Liver Neoplasms | 5 | 2013 | 4557 | 0.140 |
Why?
|
| Kidney Neoplasms | 1 | 2010 | 3022 | 0.140 |
Why?
|
| Smad4 Protein | 2 | 2014 | 196 | 0.140 |
Why?
|
| Feedback, Physiological | 3 | 2012 | 193 | 0.140 |
Why?
|
| Mice, Transgenic | 9 | 2014 | 4143 | 0.140 |
Why?
|
| Chi-Square Distribution | 3 | 2015 | 1323 | 0.140 |
Why?
|
| Carboxylesterase | 1 | 2015 | 33 | 0.130 |
Why?
|
| Cell Cycle | 5 | 2014 | 2084 | 0.130 |
Why?
|
| Cell Movement | 5 | 2014 | 2466 | 0.130 |
Why?
|
| Predictive Value of Tests | 5 | 2015 | 4892 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2015 | 3821 | 0.130 |
Why?
|
| Tumor Burden | 4 | 2015 | 1987 | 0.130 |
Why?
|
| Mice, Nude | 9 | 2014 | 4307 | 0.130 |
Why?
|
| Keratan Sulfate | 1 | 2014 | 11 | 0.130 |
Why?
|
| Mitotic Index | 1 | 2015 | 162 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2014 | 476 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2014 | 2054 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 7 | 2011 | 2508 | 0.130 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2014 | 38 | 0.130 |
Why?
|
| Mucin-1 | 1 | 2015 | 127 | 0.130 |
Why?
|
| Esophagus | 2 | 2008 | 553 | 0.130 |
Why?
|
| Cell Growth Processes | 3 | 2010 | 342 | 0.130 |
Why?
|
| Cholecystectomy | 1 | 2015 | 107 | 0.130 |
Why?
|
| Astrocytoma | 3 | 2008 | 321 | 0.120 |
Why?
|
| Fluorouracil | 6 | 2015 | 1944 | 0.120 |
Why?
|
| CDX2 Transcription Factor | 2 | 2015 | 37 | 0.120 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2014 | 23 | 0.120 |
Why?
|
| Cell Aggregation | 1 | 2013 | 61 | 0.120 |
Why?
|
| Neoplasm Grading | 3 | 2014 | 1742 | 0.120 |
Why?
|
| Microarray Analysis | 2 | 2012 | 392 | 0.120 |
Why?
|
| I-kappa B Proteins | 2 | 2012 | 170 | 0.120 |
Why?
|
| Cadherins | 2 | 2014 | 660 | 0.120 |
Why?
|
| Cystadenocarcinoma, Mucinous | 1 | 2013 | 21 | 0.110 |
Why?
|
| Estrogens | 1 | 1997 | 751 | 0.110 |
Why?
|
| Aminolevulinic Acid | 1 | 2013 | 19 | 0.110 |
Why?
|
| Jurkat Cells | 1 | 2013 | 311 | 0.110 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2013 | 84 | 0.110 |
Why?
|
| Survival Analysis | 7 | 2015 | 9180 | 0.110 |
Why?
|
| Mesenteric Veins | 1 | 2013 | 73 | 0.110 |
Why?
|
| STAT3 Transcription Factor | 2 | 2014 | 1121 | 0.110 |
Why?
|
| Combined Modality Therapy | 8 | 2014 | 8865 | 0.110 |
Why?
|
| Breast Neoplasms | 7 | 2011 | 15694 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 5 | 2014 | 5395 | 0.110 |
Why?
|
| Nervous System | 1 | 2013 | 165 | 0.110 |
Why?
|
| Inflammation | 2 | 2013 | 2522 | 0.110 |
Why?
|
| Carrier Proteins | 2 | 2013 | 2022 | 0.110 |
Why?
|
| Neoplasm Transplantation | 3 | 2011 | 1519 | 0.110 |
Why?
|
| Photochemotherapy | 1 | 2013 | 96 | 0.110 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2013 | 194 | 0.110 |
Why?
|
| Acinar Cells | 1 | 2012 | 53 | 0.110 |
Why?
|
| Cdc20 Proteins | 1 | 2012 | 25 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 4 | 2007 | 1165 | 0.110 |
Why?
|
| Zinc | 1 | 2013 | 188 | 0.110 |
Why?
|
| Lactic Acid | 1 | 2014 | 305 | 0.110 |
Why?
|
| Islets of Langerhans | 1 | 2013 | 229 | 0.110 |
Why?
|
| Diphosphonates | 1 | 2014 | 262 | 0.110 |
Why?
|
| RNA Interference | 6 | 2013 | 1408 | 0.110 |
Why?
|
| HEK293 Cells | 2 | 2013 | 1489 | 0.110 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2012 | 29 | 0.110 |
Why?
|
| Pancreatitis, Chronic | 2 | 2012 | 116 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2014 | 973 | 0.100 |
Why?
|
| Risk Factors | 6 | 2015 | 17523 | 0.100 |
Why?
|
| Gastrinoma | 1 | 2011 | 25 | 0.100 |
Why?
|
| Transcription Factor RelA | 1 | 2012 | 184 | 0.100 |
Why?
|
| Apoptosis | 8 | 2014 | 7591 | 0.100 |
Why?
|
| Plant Extracts | 1 | 2014 | 215 | 0.100 |
Why?
|
| Cell Culture Techniques | 1 | 2014 | 598 | 0.100 |
Why?
|
| Gastrins | 1 | 2011 | 55 | 0.100 |
Why?
|
| Cation Transport Proteins | 1 | 2013 | 199 | 0.100 |
Why?
|
| Interleukin-1alpha | 1 | 2012 | 56 | 0.100 |
Why?
|
| Diet, High-Fat | 1 | 2013 | 241 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2010 | 1248 | 0.100 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 131 | 0.100 |
Why?
|
| Disease Models, Animal | 9 | 2014 | 7222 | 0.100 |
Why?
|
| NADPH Oxidases | 1 | 2012 | 146 | 0.100 |
Why?
|
| Keratins | 2 | 2009 | 330 | 0.100 |
Why?
|
| Biliary Tract Diseases | 1 | 2011 | 61 | 0.100 |
Why?
|
| Prodrugs | 1 | 2013 | 217 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 2 | 2008 | 1547 | 0.100 |
Why?
|
| Epithelium | 2 | 2014 | 720 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2010 | 1648 | 0.100 |
Why?
|
| Cell Hypoxia | 2 | 2009 | 328 | 0.100 |
Why?
|
| Transcription, Genetic | 3 | 2014 | 3154 | 0.100 |
Why?
|
| Antineoplastic Agents | 9 | 2012 | 14289 | 0.100 |
Why?
|
| Retinal Dehydrogenase | 1 | 2011 | 91 | 0.100 |
Why?
|
| Galectin 3 | 1 | 2012 | 138 | 0.100 |
Why?
|
| Cyclin D2 | 1 | 2010 | 40 | 0.100 |
Why?
|
| Incidental Findings | 1 | 2012 | 272 | 0.100 |
Why?
|
| Exonucleases | 1 | 2010 | 51 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2013 | 639 | 0.100 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2010 | 37 | 0.100 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2014 | 376 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2014 | 488 | 0.100 |
Why?
|
| Sp1 Transcription Factor | 2 | 2010 | 188 | 0.090 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2011 | 141 | 0.090 |
Why?
|
| Isoenzymes | 2 | 2011 | 614 | 0.090 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2010 | 46 | 0.090 |
Why?
|
| Watchful Waiting | 1 | 2012 | 289 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 669 | 0.090 |
Why?
|
| Oligodendroglioma | 2 | 2008 | 106 | 0.090 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2008 | 161 | 0.090 |
Why?
|
| Length of Stay | 2 | 2007 | 1900 | 0.090 |
Why?
|
| Metaplasia | 1 | 2011 | 383 | 0.090 |
Why?
|
| 14-3-3 Proteins | 1 | 2010 | 143 | 0.090 |
Why?
|
| Rats | 6 | 2012 | 6086 | 0.090 |
Why?
|
| Jejunal Neoplasms | 1 | 2009 | 34 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2014 | 810 | 0.090 |
Why?
|
| Young Adult | 6 | 2014 | 21445 | 0.090 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2011 | 229 | 0.090 |
Why?
|
| Ileal Neoplasms | 1 | 2009 | 47 | 0.090 |
Why?
|
| Texas | 4 | 2014 | 6311 | 0.090 |
Why?
|
| Nanoparticles | 1 | 2014 | 554 | 0.090 |
Why?
|
| Carcinoma, Papillary | 1 | 2013 | 584 | 0.090 |
Why?
|
| Phenols | 1 | 2010 | 107 | 0.090 |
Why?
|
| DNA Primers | 4 | 2014 | 1399 | 0.090 |
Why?
|
| Splenomegaly | 1 | 2010 | 158 | 0.090 |
Why?
|
| Transcription Factors | 5 | 2014 | 5270 | 0.090 |
Why?
|
| Hedgehog Proteins | 1 | 2012 | 424 | 0.090 |
Why?
|
| Base Sequence | 5 | 2014 | 4917 | 0.090 |
Why?
|
| Colitis | 1 | 2012 | 340 | 0.090 |
Why?
|
| Sjogren's Syndrome | 1 | 2010 | 102 | 0.090 |
Why?
|
| Glycolysis | 1 | 2012 | 519 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2009 | 45 | 0.090 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2011 | 192 | 0.090 |
Why?
|
| DNA Damage | 3 | 2012 | 1954 | 0.090 |
Why?
|
| Neuropilin-2 | 1 | 2008 | 21 | 0.080 |
Why?
|
| Liver | 2 | 2006 | 2961 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2009 | 134 | 0.080 |
Why?
|
| Clinical Competence | 2 | 2007 | 1270 | 0.080 |
Why?
|
| Genes, erbB-2 | 1 | 2009 | 229 | 0.080 |
Why?
|
| Follow-Up Studies | 7 | 2014 | 14889 | 0.080 |
Why?
|
| Receptors, Progesterone | 1 | 2014 | 1392 | 0.080 |
Why?
|
| MicroRNAs | 2 | 2013 | 2947 | 0.080 |
Why?
|
| Lipocalins | 1 | 2008 | 54 | 0.080 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2010 | 270 | 0.080 |
Why?
|
| Multiprotein Complexes | 1 | 2011 | 395 | 0.080 |
Why?
|
| Acute-Phase Proteins | 1 | 2008 | 79 | 0.080 |
Why?
|
| Antigens, CD | 2 | 2011 | 1385 | 0.080 |
Why?
|
| Gliosarcoma | 1 | 2008 | 29 | 0.080 |
Why?
|
| Plicamycin | 1 | 2007 | 30 | 0.080 |
Why?
|
| Hepatectomy | 3 | 2010 | 1011 | 0.080 |
Why?
|
| BRCA2 Protein | 1 | 2010 | 358 | 0.080 |
Why?
|
| Tissue Banks | 1 | 2008 | 55 | 0.080 |
Why?
|
| Paget Disease, Extramammary | 1 | 2008 | 55 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2009 | 287 | 0.080 |
Why?
|
| Mutation | 9 | 2014 | 15179 | 0.080 |
Why?
|
| Databases as Topic | 1 | 2008 | 133 | 0.080 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 355 | 0.080 |
Why?
|
| Escherichia coli | 3 | 2000 | 1203 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2011 | 747 | 0.080 |
Why?
|
| Microsatellite Instability | 1 | 2009 | 400 | 0.080 |
Why?
|
| Heterografts | 3 | 2014 | 733 | 0.080 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2008 | 69 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2011 | 507 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 1493 | 0.080 |
Why?
|
| Paclitaxel | 1 | 2014 | 1996 | 0.080 |
Why?
|
| Fibroma | 1 | 2007 | 85 | 0.080 |
Why?
|
| Mesoderm | 1 | 2009 | 404 | 0.070 |
Why?
|
| Biopsy | 3 | 2015 | 3443 | 0.070 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 509 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2003 | 4654 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2011 | 589 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 2 | 2013 | 1443 | 0.070 |
Why?
|
| Annexin A1 | 1 | 2006 | 39 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2014 | 3552 | 0.070 |
Why?
|
| Cells, Cultured | 3 | 2013 | 5637 | 0.070 |
Why?
|
| Lysine | 1 | 2008 | 422 | 0.070 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2006 | 189 | 0.070 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2004 | 243 | 0.070 |
Why?
|
| Diagnostic Imaging | 2 | 2011 | 1162 | 0.070 |
Why?
|
| Mice, SCID | 4 | 2011 | 1869 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 1399 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2008 | 299 | 0.070 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2015 | 1217 | 0.070 |
Why?
|
| Bevacizumab | 4 | 2010 | 938 | 0.070 |
Why?
|
| Heart Neoplasms | 1 | 2007 | 214 | 0.070 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2010 | 854 | 0.070 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2006 | 178 | 0.060 |
Why?
|
| Peptides | 1 | 2011 | 1479 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 1546 | 0.060 |
Why?
|
| Mitochondria | 1 | 2012 | 1282 | 0.060 |
Why?
|
| Glioblastoma | 2 | 2008 | 1797 | 0.060 |
Why?
|
| Ubiquitination | 3 | 2014 | 575 | 0.060 |
Why?
|
| Indoles | 1 | 2010 | 1009 | 0.060 |
Why?
|
| Cell Survival | 4 | 2014 | 3045 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2000 | 2063 | 0.060 |
Why?
|
| Biomarkers | 2 | 2014 | 5047 | 0.060 |
Why?
|
| Lymph Node Excision | 1 | 2011 | 1959 | 0.060 |
Why?
|
| Cytochrome P-450 CYP3A | 3 | 2000 | 83 | 0.060 |
Why?
|
| Receptor, ErbB-2 | 2 | 2013 | 2518 | 0.060 |
Why?
|
| beta Catenin | 1 | 2007 | 688 | 0.060 |
Why?
|
| DNA Adducts | 2 | 2014 | 210 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2010 | 1863 | 0.060 |
Why?
|
| Carcinoid Tumor | 1 | 2005 | 280 | 0.060 |
Why?
|
| Cell Line, Transformed | 2 | 2014 | 394 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2011 | 5178 | 0.060 |
Why?
|
| Hydroxylation | 2 | 2000 | 65 | 0.060 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2006 | 323 | 0.060 |
Why?
|
| Agglutinins | 1 | 2002 | 19 | 0.060 |
Why?
|
| Phenotype | 1 | 2014 | 6295 | 0.060 |
Why?
|
| COP9 Signalosome Complex | 2 | 2014 | 72 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2014 | 6869 | 0.050 |
Why?
|
| Ceruletide | 2 | 2012 | 27 | 0.050 |
Why?
|
| Chemoradiotherapy | 1 | 2011 | 1946 | 0.050 |
Why?
|
| Melanocytes | 1 | 2003 | 219 | 0.050 |
Why?
|
| Cisplatin | 4 | 2013 | 2432 | 0.050 |
Why?
|
| DNA, Neoplasm | 3 | 2014 | 1910 | 0.050 |
Why?
|
| Barrett Esophagus | 1 | 2008 | 569 | 0.050 |
Why?
|
| Liver Diseases | 1 | 2007 | 574 | 0.050 |
Why?
|
| Testicular Diseases | 1 | 2002 | 22 | 0.050 |
Why?
|
| Cryptorchidism | 1 | 2002 | 40 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2007 | 1073 | 0.050 |
Why?
|
| HCT116 Cells | 2 | 2014 | 348 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2012 | 3251 | 0.050 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2006 | 486 | 0.050 |
Why?
|
| NF-KappaB Inhibitor alpha | 2 | 2012 | 136 | 0.050 |
Why?
|
| Capecitabine | 2 | 2014 | 388 | 0.050 |
Why?
|
| Histocytochemistry | 1 | 2002 | 185 | 0.050 |
Why?
|
| GTP-Binding Proteins | 3 | 2008 | 321 | 0.050 |
Why?
|
| Gene Expression Regulation | 3 | 2013 | 4053 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2003 | 253 | 0.050 |
Why?
|
| Chemokines | 1 | 2003 | 314 | 0.050 |
Why?
|
| Necrosis | 1 | 2002 | 580 | 0.050 |
Why?
|
| Histones | 1 | 2008 | 1466 | 0.050 |
Why?
|
| Androstenedione | 1 | 2000 | 18 | 0.050 |
Why?
|
| Central Nervous System Depressants | 1 | 2000 | 26 | 0.050 |
Why?
|
| Aurora Kinases | 2 | 2012 | 189 | 0.050 |
Why?
|
| Gene Knock-In Techniques | 2 | 2012 | 171 | 0.050 |
Why?
|
| Dehydroepiandrosterone | 1 | 2000 | 38 | 0.050 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2013 | 460 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2013 | 3518 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 3343 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2007 | 1415 | 0.050 |
Why?
|
| Phosphorylation | 3 | 2013 | 4804 | 0.050 |
Why?
|
| Proteins | 1 | 2008 | 1963 | 0.050 |
Why?
|
| Amyloidosis | 1 | 2002 | 176 | 0.050 |
Why?
|
| Aurora Kinase A | 2 | 2012 | 202 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2008 | 690 | 0.040 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2002 | 294 | 0.040 |
Why?
|
| Gene Silencing | 2 | 2014 | 837 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2000 | 548 | 0.040 |
Why?
|
| Multiple Myeloma | 1 | 2010 | 2138 | 0.040 |
Why?
|
| Matrix Metalloproteinase 2 | 3 | 2005 | 256 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 2000 | 388 | 0.040 |
Why?
|
| Cytokines | 2 | 2012 | 2809 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2011 | 2927 | 0.040 |
Why?
|
| Tumor Microenvironment | 3 | 2014 | 2864 | 0.040 |
Why?
|
| Ethanol | 1 | 2000 | 264 | 0.040 |
Why?
|
| Cyclosporine | 1 | 1999 | 278 | 0.040 |
Why?
|
| Endometrial Neoplasms | 1 | 2008 | 1341 | 0.040 |
Why?
|
| Mice, Inbred NOD | 2 | 2011 | 905 | 0.040 |
Why?
|
| NADPH-Ferrihemoprotein Reductase | 1 | 1997 | 4 | 0.040 |
Why?
|
| Transcriptional Activation | 2 | 2013 | 1070 | 0.040 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 1997 | 21 | 0.040 |
Why?
|
| DNA, Complementary | 2 | 1996 | 869 | 0.040 |
Why?
|
| Neoplasm Metastasis | 3 | 2014 | 5112 | 0.040 |
Why?
|
| Enzyme Induction | 2 | 2012 | 249 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2002 | 2232 | 0.040 |
Why?
|
| Skin | 1 | 2002 | 1259 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 4549 | 0.040 |
Why?
|
| Cell Adhesion | 2 | 2010 | 1008 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 1996 | 16 | 0.040 |
Why?
|
| Macrophages | 1 | 2003 | 1304 | 0.040 |
Why?
|
| Protein Binding | 2 | 2014 | 3438 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2002 | 1146 | 0.030 |
Why?
|
| Ovariectomy | 1 | 1997 | 330 | 0.030 |
Why?
|
| Mutagenesis | 1 | 1997 | 483 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2010 | 7702 | 0.030 |
Why?
|
| Testosterone | 1 | 2000 | 619 | 0.030 |
Why?
|
| Neoplasms | 2 | 2014 | 15193 | 0.030 |
Why?
|
| Adolescent | 5 | 2014 | 31252 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 5767 | 0.030 |
Why?
|
| Prospective Studies | 4 | 2014 | 12873 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1996 | 682 | 0.030 |
Why?
|
| Liposomes | 1 | 1997 | 684 | 0.030 |
Why?
|
| Glutathione | 1 | 1997 | 368 | 0.030 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2014 | 42 | 0.030 |
Why?
|
| Microscopy, Confocal | 2 | 2008 | 663 | 0.030 |
Why?
|
| Cell Line | 1 | 2003 | 5114 | 0.030 |
Why?
|
| Lumican | 1 | 2014 | 22 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2014 | 249 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 1997 | 417 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2014 | 88 | 0.030 |
Why?
|
| Extracellular Space | 1 | 2014 | 132 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 4938 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2014 | 191 | 0.030 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2014 | 16 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2008 | 1391 | 0.030 |
Why?
|
| E2F Transcription Factors | 1 | 2014 | 132 | 0.030 |
Why?
|
| Biological Transport, Active | 1 | 2014 | 131 | 0.030 |
Why?
|
| Family Health | 1 | 2015 | 325 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2014 | 155 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 5539 | 0.030 |
Why?
|
| Models, Biological | 2 | 2014 | 3254 | 0.030 |
Why?
|
| Estradiol | 1 | 1997 | 748 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 573 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 1213 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2011 | 3033 | 0.030 |
Why?
|
| raf Kinases | 1 | 2013 | 81 | 0.030 |
Why?
|
| General Surgery | 2 | 2007 | 326 | 0.030 |
Why?
|
| Triiodobenzoic Acids | 1 | 2013 | 68 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 2 | 2008 | 545 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2007 | 16273 | 0.030 |
Why?
|
| Biological Transport | 1 | 2014 | 597 | 0.030 |
Why?
|
| Leucovorin | 1 | 2014 | 332 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 1999 | 1375 | 0.030 |
Why?
|
| Survival | 1 | 2013 | 177 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 245 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 875 | 0.030 |
Why?
|
| Albumins | 1 | 2014 | 258 | 0.030 |
Why?
|
| Child | 4 | 2014 | 29154 | 0.030 |
Why?
|
| NADPH Oxidase 1 | 1 | 2012 | 7 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2013 | 5710 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 702 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 550 | 0.030 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2012 | 26 | 0.030 |
Why?
|
| Gabexate | 1 | 2012 | 3 | 0.030 |
Why?
|
| Esters | 1 | 2012 | 45 | 0.030 |
Why?
|
| Sincalide | 1 | 2012 | 37 | 0.030 |
Why?
|
| Bilirubin | 1 | 2013 | 221 | 0.030 |
Why?
|
| Protein Transport | 1 | 2014 | 734 | 0.030 |
Why?
|
| Sequestosome-1 Protein | 1 | 2012 | 39 | 0.030 |
Why?
|
| Guanidines | 1 | 2012 | 60 | 0.030 |
Why?
|
| Colonic Neoplasms | 2 | 2010 | 1390 | 0.030 |
Why?
|
| Light | 1 | 2013 | 245 | 0.030 |
Why?
|
| Tumor Protein p73 | 1 | 2012 | 105 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2014 | 382 | 0.030 |
Why?
|
| Tetracycline | 1 | 2012 | 90 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 518 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 2011 | 130 | 0.030 |
Why?
|
| Trefoil Factor-1 | 1 | 2011 | 15 | 0.030 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2012 | 111 | 0.030 |
Why?
|
| Cell Death | 1 | 2014 | 671 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 651 | 0.030 |
Why?
|
| Adiposity | 1 | 2013 | 237 | 0.030 |
Why?
|
| Infant | 2 | 2007 | 13310 | 0.030 |
Why?
|
| AC133 Antigen | 1 | 2011 | 110 | 0.030 |
Why?
|
| CD24 Antigen | 1 | 2011 | 85 | 0.020 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2012 | 161 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2012 | 266 | 0.020 |
Why?
|
| Dissection | 1 | 2011 | 156 | 0.020 |
Why?
|
| MafB Transcription Factor | 1 | 2010 | 12 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2014 | 1313 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2014 | 750 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2012 | 200 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2013 | 798 | 0.020 |
Why?
|
| Anisoles | 1 | 2010 | 2 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2012 | 246 | 0.020 |
Why?
|
| Decision Trees | 1 | 2011 | 178 | 0.020 |
Why?
|
| Exoribonucleases | 1 | 2010 | 42 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 1 | 2012 | 253 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 324 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 298 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2011 | 249 | 0.020 |
Why?
|
| DNA Replication | 1 | 2014 | 744 | 0.020 |
Why?
|
| Plasmids | 1 | 2012 | 837 | 0.020 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2010 | 92 | 0.020 |
Why?
|
| Mullerian Ducts | 1 | 2010 | 76 | 0.020 |
Why?
|
| Abdomen | 1 | 2011 | 332 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 1996 | 4233 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2012 | 558 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2010 | 202 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 423 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2014 | 884 | 0.020 |
Why?
|
| Constipation | 1 | 2010 | 177 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 11538 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2010 | 234 | 0.020 |
Why?
|
| Vaginal Neoplasms | 1 | 2010 | 152 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2014 | 852 | 0.020 |
Why?
|
| Cell Separation | 1 | 2011 | 612 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 634 | 0.020 |
Why?
|
| Platelet Count | 1 | 2010 | 490 | 0.020 |
Why?
|
| Mucoproteins | 1 | 2008 | 25 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2009 | 260 | 0.020 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2008 | 85 | 0.020 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2009 | 159 | 0.020 |
Why?
|
| Jagged-1 Protein | 1 | 2008 | 101 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 6089 | 0.020 |
Why?
|
| Thyroid Gland | 1 | 2011 | 355 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2008 | 60 | 0.020 |
Why?
|
| Lipocalin-2 | 1 | 2008 | 65 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2010 | 557 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 543 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 6942 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2010 | 467 | 0.020 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2008 | 42 | 0.020 |
Why?
|
| Thioredoxins | 1 | 2008 | 50 | 0.020 |
Why?
|
| Dogs | 1 | 2009 | 1155 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2010 | 369 | 0.020 |
Why?
|
| Spleen | 1 | 2010 | 676 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 1618 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 1904 | 0.020 |
Why?
|
| Reoperation | 1 | 2012 | 1382 | 0.020 |
Why?
|
| Rosaniline Dyes | 1 | 2007 | 108 | 0.020 |
Why?
|
| Proteomics | 1 | 2014 | 1380 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2011 | 943 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 534 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2010 | 584 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 987 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2010 | 519 | 0.020 |
Why?
|
| Contrast Media | 1 | 2013 | 1472 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2009 | 1062 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2008 | 591 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 1053 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2008 | 354 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2007 | 223 | 0.020 |
Why?
|
| Binding Sites | 1 | 2010 | 2171 | 0.020 |
Why?
|
| Duodenoscopy | 1 | 2005 | 18 | 0.020 |
Why?
|
| Papanicolaou Test | 1 | 2007 | 141 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 2292 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 665 | 0.020 |
Why?
|
| Lymphoma | 1 | 2014 | 1467 | 0.020 |
Why?
|
| Vaginal Smears | 1 | 2007 | 192 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2008 | 375 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2009 | 1643 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 1688 | 0.020 |
Why?
|
| CD146 Antigen | 1 | 2005 | 57 | 0.020 |
Why?
|
| Observer Variation | 1 | 2007 | 671 | 0.020 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2005 | 55 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2010 | 1245 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2008 | 1487 | 0.020 |
Why?
|
| Transcription Factor AP-2 | 1 | 2005 | 79 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2008 | 402 | 0.020 |
Why?
|
| Hysterectomy | 1 | 2008 | 611 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2012 | 1664 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 392 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2009 | 795 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 2049 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 3101 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2005 | 479 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2015 | 9244 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 1085 | 0.010 |
Why?
|
| Oligospermia | 1 | 2002 | 67 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 4320 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2010 | 3842 | 0.010 |
Why?
|
| Esophagectomy | 1 | 2007 | 911 | 0.010 |
Why?
|
| Rectal Neoplasms | 1 | 2010 | 1202 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 2283 | 0.010 |
Why?
|
| Chromosomes, Human | 1 | 2002 | 295 | 0.010 |
Why?
|
| Chlorzoxazone | 1 | 2000 | 2 | 0.010 |
Why?
|
| Steroid Hydroxylases | 1 | 2000 | 36 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2008 | 1824 | 0.010 |
Why?
|
| Troleandomycin | 1 | 1999 | 1 | 0.010 |
Why?
|
| Ketoconazole | 1 | 1999 | 34 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2006 | 1678 | 0.010 |
Why?
|
| Dietary Carbohydrates | 1 | 2000 | 134 | 0.010 |
Why?
|
| Biotransformation | 1 | 1999 | 93 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2008 | 1423 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2000 | 549 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 4971 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 862 | 0.010 |
Why?
|
| Dietary Fats | 1 | 2000 | 339 | 0.010 |
Why?
|
| Patient Selection | 1 | 2006 | 2055 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 1533 | 0.010 |
Why?
|
| Enteral Nutrition | 1 | 2000 | 316 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2008 | 2819 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 2002 | 1005 | 0.010 |
Why?
|
| United States | 1 | 2015 | 15433 | 0.010 |
Why?
|
| Testicular Neoplasms | 1 | 2002 | 529 | 0.010 |
Why?
|
| Testis | 1 | 2002 | 717 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2002 | 1442 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 3869 | 0.010 |
Why?
|
| Incidence | 1 | 2007 | 5673 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2007 | 6009 | 0.010 |
Why?
|
| Diet | 1 | 2000 | 1440 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2008 | 5542 | 0.010 |
Why?
|